Trials / Unknown
UnknownNCT04988789
Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access Dysfunction
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Singapore General Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- —
Summary
Recent studies of paclitaxel DCB in the treatment of stenosis at dialysis vascular access have shown promising results. Paclitaxel, an anti-proliferation drug, is released during balloon inflation and potentially improve primary patency by slowing down NIH effect. However, meta-analysis have suggested that the use of paclitaxel in lower limbs have increased risk of death in patients. The effect of paclitaxel DCB on dialysis access however remains unknown. Hence, we aim to set up a database to track long-term treatment outcomes of patients treated with Paclitaxel DCB at SGH for their stenosed dialysis access
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel Drug Coated Balloon | Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-08-04
- Last updated
- 2021-08-04
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT04988789. Inclusion in this directory is not an endorsement.